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A new consensus for evaluating CDKL5/
STK9-dependent signalling mechanisms
Patrick A Eyers
Mutation or inactivation of CDKL5 kinase is
associated with a human neurodevelop-
mental condition commonly referred to as
CDKL5 deficiency disorder.§ Two recent
phosphoproteomics studies identify the
first physiological substrates of mamma-
lian CDKL5 and evaluate functional conse-
quences of their phosphorylation and its
loss in cells lacking functional CDKL5, high-
lighting potential roles for this kinase in
regulating neuronal microtubule dynamics.
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P rotein phosphorylation plays a funda-mental role in basic cell biology, andthe protein kinase superfamily has
become a goldmine for potential drug-inter-
vention strategies due to kinase mutation or
dysregulation in human diseases. However,
it is often (conveniently) forgotten that
mechanistic information is lacking for much
of the human kinome, and this includes an
absence of basic knowledge pertaining to
regulatory mechanisms and substrate speci-
ficity (Wilson et al, 2018). A case-in-point
are the cyclin-dependent kinase-like (CDKL)
kinases, a small family of five poorly charac-
terised and structurally distinct Ser/Thr
protein kinases from the CGMC evolutionary
branch of the kinome, which contains
GSK3a, MAPK and CDK families (Canning
et al, 2018). Mammalian CDKL5 (also
known as STK9) is widely expressed in cells,
where it is targeted to a variety of subcellu-
lar structures (Barbiero et al, 2017; Oi et al,
2017). Of particular interest, inactivation of
the X-linked CDKL5 gene, or disease-asso-
ciated mutations commonly found in the N-
terminal CDKL5 catalytic domain, causes a
neurodevelopmental disorder termed CDKL5
deficiency disorder (CDD; Tao et al, 2004;
Weaving et al, 2004), which has some over-
lapping features with Rett syndrome (Scala
et al, 2005) and West syndrome (Kalscheuer
et al, 2003).§
Writing in The EMBO Journal, two
groups simultaneously reveal the first physi-
ological substrates for CDKL5, including
potential new biomarkers for reporting cellu-
lar CDKL5 activity. Using distinct, but highly
complementary mass spectrometry (MS)-
based phosphoproteomics approaches, the
laboratories of John Rouse and Matthias
Trost (Mun˜oz et al, 2018), and Sila Ultanir
(Baltussen et al, 2018) evaluate functional
consequences of CDKL5-catalysed substrate
phosphorylation and its loss in cells lacking
functional CDKL5. These findings will be
critical for understanding microtubule
dynamics and cilium-based signalling in
CDD cell models, including neurons from
patients with pathological CDKL5 mutations.
Both teams exploited MS to establish, in
as unambiguous a way as is possible, the
direct substrates of CDKL5 in cellular
models. Although the approaches taken were
different, they (happily) converge on a
subset of substrates related both through
shared subcellular function(s) and conserved
consensus site(s) of CDKL5 phosphorylation.
Mun˜oz and colleagues initially employed a
clean CRISPR knockout/in approach in
human U2OS cells  CDKL5, which was
coupled to a quantitative (6-plex TMT) phos-
phoproteomic workflow (Mun˜oz et al, 2018).
This high-quality, internally controlled
experimental strategy revealed nearly 200
sites of intracellular protein phosphorylation
(including CDKL5 autophosphorylation)
whose increase was statistically relevant
when CDKL5 was added back to CDKL5
genome-edited cells. In a distinct, no-less
impressive approach, Baltussen and collea-
gues developed CDKL5 chemical proteomics,
employing purified catalytically active
CDKL5-F89A/C152A, an analogue-sensitive
(as) version selectively using the bulky ATP
analogue benzyl-ATPcS, to thiophosphory-
late potential substrates in a mouse brain
lysate (Baltussen et al, 2018). After affinity-
based purification of phosphorylated
substrate-derived peptides, mass spectrome-
try identified multiple potential CDKL5
substrates, including murine microtubule-
associated targets MAP1S (two sites of phos-
phorylation), EB2 and ARHGEF2 (Baltussen
et al, 2018) and, independently, human
MAP1S, CEP131 and DLG5 (Mun˜oz et al,
2018). At a single stroke, these consolidating
approaches reveal, for the very first time,
new signalling functions of CDKL5 that are
relevant to microtubule assembly, cilia-
based signalling and perhaps polarity-based
cellular networks (Fig 1A).
In the case of the microtubule-binding
protein MAP1S, a biological function for
phosphorylation was confirmed in elegant
murine follow-up experiments, exploiting
phospho-specific MAP1S antibodies to
demonstrate that phosphorylation on Ser812
(equivalent to human Ser900) was impaired
in microtubule binding in vitro, consistent
with a significant reduction in microtubule
dynamics in living cortical neuron dendrites
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derived from CDKL5 knockout mice
(Baltussen et al, 2018). In order to probe
signalling with additional reagents, both
studies made use of additional phospho-
specific antibodies. For example, the phos-
phorylation of MAP1S at Ser812 and EB2 at
Ser222 is both markedly reduced in CDKL5
knockout mice regardless of age, validating
phosphoproteomics data and establishing
CDKL5 activity markers in cells based
around proteins that modulate microtubule
trafficking and dynamics (Fig 1B). Perhaps
the icing on the cake, however, is the
demonstration that endogenous EB2 phos-
phorylation (as judged by a phospho-specific
EB2 antibody able to recognise an identical
phospho-epitope in human and mouse EB2)
is severely reduced (by ~80%) in neurons
derived from CDD patient fibroblasts after
reprogramming into iSPCs (Baltussen et al,
2018). Importantly, many of the antibodies
validated in the two studies can now be
employed, or re-engineered as higher-affinity
antibodies, to serve as diagnostic tools for
quantifying cellular activity of CDKL5, most
obviously to evaluate CDKL5 biology and
diagnose CDKL5 phenotypes, but also for
therapeutic approaches being developed to
normalise CDKL5 expression (see below).
Another exciting outcome from these
studies is the finding that catalytically active
CDKL5 phosphorylates Ser/Thr in a sharply
defined, specific amino acid consensus
sequence in its target substrates (Fig 1A), as
has been documented for many other protein
kinases. A harmonious minimal CDKL5
phosphorylation consensus emerging from
both papers is the amino acid sequence Arg-
Pro-X-Ser/Thr-Ala/Pro, in which the Ser or
Thr residue (heavily biased 85:15% Ser:Thr)
is phosphorylated, adjacent to a C-terminal
residue (commonly Ala or Pro). These latter
findings, confirmed biochemically with
model peptide substrates, agree with phos-
phoproteomics data sets, which demon-
strated CDKL5 autophosphorylation sites in
Ser/Pro motifs alongside a dominant general
Arg-X-X-Ser motif (Mun˜oz et al, 2018).
Although the CDKL5 consensus overlaps to
some extent with known sites of phosphory-
lation for other “basophilic” kinases (e.g.
Arg-X-X-Ser-Ala for several AGC kinases)
and MAPK/CDKs (minimally Ser/Thr-Pro),
the absolute conservation of a Pro at 2, and
a specific requirement for Arg at 3, may
well be diagnostic for CDKL5 (and perhaps
other CDKL orthologues). Further studies
employing active CDKL1/2/3/4 proteins
(which, somewhat surprisingly, do not
appear to phosphorylate any of the physio-
logical CDKL5 substrates identified in this
study) should open up these unstudied
human kinases to careful scrutiny using
similar chemical genetic or genome editing
approaches.
The functional consequences of patholog-
ical CDKL5 mutations were previously
uncertain, with evidence for inhibition and
preservation of activity, alongside Tyr phos-
phorylation in the TEY activation segment
(Bertani et al, 2006). By quantifying the
reduction of CDKL5-dependent MAP1S and
CEP131 phosphorylation in cells expressing
specific CDD mutants, and by using a new
MAP1S S900 peptide assay to assess
immunoprecipitated CDKL5 activity, Mun˜oz
and colleagues now unequivocally identify
them as loss-of-function mutations that inac-
tivate CDKL5.
Intriguingly, biochemical analysis
demonstrates that CDKL5 also possesses an
inherent ability to phosphorylate itself on a
conserved regulatory residue (Tyr171) in the
activation segment Thr-Glu-Tyr motif. This
autophosphorylation event appears to be
intimately associated with an active kinase
conformation when evaluated in vitro, and
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Figure 1. Physiological CDKL5 substrates control cytoskeletal function.
(A) Through an unknown signalling mechanism, CDKL5 catalytic activity is switched on via Tyr (auto)phosphorylation in the activation segment Thr-Glu-Tyr motif. Active
CDKL5 phosphorylates various cellular pools of substrates in the consensus Arg-Pro-X-Ser-Ala, leading to phosphorylation-dependent changes in microtubule dynamics and
cargo transportation. (B) In cells containing pathology-associated CDKL5mutations, CDKL5 exhibits much reduced activity and fails to phosphorylate various target proteins.
Changes in cytoskeletal dynamics, including loss of targeted EB2 andMAP1S phosphorylation, promote abnormal microtubule functions and neuronal phenotypes associated
with CDD.
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might also be relevant for generating active
CDKL5 in cells (Bertani et al, 2006). Interest-
ingly, a Thr-X-Tyr motif is conserved in all
five human CDKL protein kinases; its muta-
tion to an Asp-X-Glu phosphomimetic
version in CDKL1-5 prior to crystallographic
studies (Canning et al, 2018) provides
supporting evidence of the importance of
this motif for driving structural dynamics.
However, how (or even whether) CDKL5
phosphorylation is regulated at this motif in
cells remains to be established, since the
mechanism through which it is triggered is
currently unknown. It is intriguing to specu-
late that CDKL5 is not only able to control
its own activity, but that mutations in CDD
patients might also lead to a loss in CDKL5
catalytic output through a lack of activation-
loop Tyr phosphorylation. The best-known
“dual-specificity” protein kinases are the
MAPKK/MEK family of MAPK activators,
which catalyse dual phosphorylation of a
Thr-X-Tyr motif (Thr-Glu-Tyr for MEK1/2)
in the activation segment of cognate MAPK
substrates. A concerted autoactivation mech-
anism in CDKL5 suggests that it possesses
(biochemical) properties of a dual-specificity
protein kinase, and opens up this mechanis-
tic event in CDKL kinases for further analysis.
In the related MAPKs, dual phosphorylation
of the Thr-X-Tyr motif massively increases
catalytic activity, whereas Tyr15 phosphory-
lation is strongly associated with inhibition
at a motif distinct from the activation
segment in CDKs. It will therefore be inter-
esting to evaluate whether CDKL5 autophos-
phorylation on Tyr (and/or Thr) also occurs
on the other four CDKL proteins (where the
human sequence is Thr-Asp-Tyr, rather than
Thr-Glu-Tyr), or whether Tyr is also phos-
phorylated on cellular proteins distinct from
CDKL5. Finally, CDKL5 Tyr autophosphory-
lation does not rule out the presence of
distinct Tyr or dual-specificity kinases lying
“upstream” of CDKL5; putative activators
include the interacting dual-specificity
tyrosine phosphorylation-regulated kinase
DYRK1A (Oi et al, 2017), which was previ-
ously shown to contribute to CDKL5 subcel-
lular targeting.
A central impact from this work is the
discovery of the very first physiological
CDKL5 substrates and the emergence of a
framework for the development of multiple
approaches to study and measure (and even-
tually normalise) CDKL5 activity in systems
relevant to CDD, such as the brain. Further
detective work will be required to uncover
the complete set of cellular CDKL5 substrates
(many more being predicted in these phos-
phoproteomics studies) and to decipher regu-
latory networks associated with CDKL5
catalytic output that are central to physiologi-
cal function and underlie CDKL5 loss-of-func-
tion in CDD. Unravelling the molecular
mechanisms of CDKL5 activation and inacti-
vation could also help link subset(s) of the
CDKL5 network that contribute to disease
phenotypes to potential therapeutics. In terms
of targetable outputs, factors that control
CDKL5 activation include pharmacological
agents linked to activity of the NMDA recep-
tor (Tramarin et al, 2018), whose inhibition
by experimental neuronal depolarisation has
a significant experimental effect on EB2 phos-
phorylation at pS222 (Baltussen et al, 2018).
Several avenues might also be explored in
related areas of cell biology, most notably
any links between human CDKL5 and the
ciliopathy-associated protein CENP131,
which is associated with centriolar stability
and the DNA damage response. Centriolar
and cilium-based analysis also provide fasci-
nating new potential models for functional
CDKL5 analysis. For example, human CDKL5
has recently been demonstrated to localise to
the cilium, and effects of patient-derived
mutations have been modelled in C. elegans,
where CeCDKL1 (most similar to human
CDKL1/4) regulates cilium length, and
Chlamydomonas, where CrCDKL5 is also
required for controlling aspects of cilial
dynamics (Canning et al, 2018).
Finally, very recent studies have begun to
analyse small molecule kinase inhibitors,
including the pre-clinical GSK3a inhibitor
tideglusib, which exhibits some promise for
restoring memory function in immature
CDKL5 knockout mice, although the specific
intracellular target that mediates these
effects is unknown (Fuchs et al, 2018).
Further work is now required to link the
specific subset(s) of phosphorylated CDKL5
targets that contribute to disease pheno-
types, and to understand the function of the
long C-terminal region, which is much
longer in CDKL5 than other CDKL proteins,
and presumably plays a key role in its physi-
ological function. Rational drug design using
recently available CDKL5 structures and
small molecule screening data (Canning
et al, 2018) could provide new ways to acti-
vate mutated (inactive) CDKL5 mutants,
alongside the development of genetic thera-
pies, or even protein-replacement therapies
(Trazzi et al, 2018).
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